Differential effects of rifampin and ketoconazole on the blood and liver concentration of atorvastatin in wild-type and cyp3a and oatp1a/b knockout mice

Drug Metabolism and Disposition

Volumn 42, Issue 6, 2014, Pages 1067-1073

  Chang, Jae H ^a   Ly, Justin ^a   Plise, Emile ^a   Zhang, Xiaolin ^a   Messick, Kirsten ^a   Wright, Matthew ^a   Cheong, Jonathan ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A; KETOCONAZOLE; MEMBRANE PROTEIN; ORGANIC ANION TRANSPORTER A; ORGANIC ANION TRANSPORTER B; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNCLASSIFIED DRUG; CYP3A PROTEIN, MOUSE; CYTOCHROME P450; HEPTANOIC ACID DERIVATIVE; ORGANIC ANION TRANSPORTER 1; PYRROLE DERIVATIVE; SLC22A6 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG UPTAKE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BLOOD; DEFICIENCY; DRUG EFFECTS; DRUG INTERACTION; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEK293 CELLS; HEPTANOIC ACIDS; HUMANS; KETOCONAZOLE; LIVER; MICE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORT PROTEIN 1; PYRROLES; RIFAMPIN;

EID: 84901011339     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057968     Document Type: Article

References (35)

1. Black AE, Sinz MW, Hayes RN, and Woolf TF (1998) Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 26:755-763.
2. Chang JH, Plise E, Cheong J, Ho Q, and Lin M (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm 10:3067-3075.
3. Chen C, Lin J, Smolarek T, and Tremaine L (2007) P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 35:1725-1729.
4. Cui Y, König J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
5. DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, and Kim RB (2012) Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b22/2 mice and intraindividual variability in human subjects. J Clin Pharmacol 52:1689-1697.
6. FDA (2012) FDA Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.
7. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
8. Grube M, Köck K, Oswald S, Draber K, Meissner K, Eckel L, Böhm M, Felix SB, Vogelgesang S, and Jedlitschky G, et al. (2006) Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80: 607-620.
9. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665.
10. Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, and Zamek-Gliszczynski MJ (2014) Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATPmediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos 42:182-192.
11. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
12. Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, and Schinkel AH (2012) Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 9:2497-2504.
13. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
14. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, and Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522.
15. Kantola T, Kivistö KT, and Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65.
16. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, and Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
17. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204.
18. Lau YY, Okochi H, Huang Y, and Benet LZ (2006a) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
19. Lau YY, Okochi H, Huang Y, and Benet LZ (2006b) Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 34:1175-1181.
20. Lea AP and McTavish D (1997) Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53:828-847.
21. Lewin JJ, 3rd, Nappi JM, and Taylor MH (2002) Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 36:1546-1549.
22. LIPITOR. (2012) Package insert. Pfizer, New York.
23. Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, and Shi GP (2010) Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther 48:798-802.
24. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, and Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575-581.
25. Matsushima S, Maeda K, Ishiguro N, Igarashi T, and Sugiyama Y (2008) Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663-669.
26. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, and Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68:391-400.
27. Scharschmidt BF, Waggoner JG, and Berk PD (1975) Hepatic organic anion uptake in the rat. J Clin Invest 56:1280-1292.
28. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, and Kim RB (2011) Identification of novel functional organic aniontransporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics 21:103-114.
29. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, and Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45-78.
30. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, and Kenworthy KE, et al. (2012) Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519-528.
31. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, and Schinkel AH (2010) Organic anion transporting polypeptide 1a/1bknockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 120:2942-2952.
32. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, and Rosing H, et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592.
33. van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, and Schinkel AH (2009) Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305-2313.
34. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, and Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215-222.
35. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.